Abstract
The NINDS t-PA Stroke Trials are two Phase IIB, randomized, double-blind trials comparing recombinant tissue plasminogen activator (t-PA) to placebo. The trials are being carried out by 8 clinical centers and 40 participating hospitals. The primary alternative hypotheses for each trial are that:
-
1.
There is a difference between the t-PA and placebo groups enrolled within 90 min of onset in the proportion showing significant early improvement; and
-
2.
There is a difference between the t-PA and placebo groups enrolled between 91 and 180 min of stroke onset in the proportion showing significant early improvement.
Division of Biostatistics and Research Epidemiology, Henry Ford Health Sciences Center, South-field, OH, USA for The NINDS t-PA Stroke Trial Investigators. Please see Appendix.
Presented by K. M. A. Welch, William T. Gossett, Chair, Department of Neurology, Henry Ford Health Sciences Center, Detroit, MI, USA
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Tilley, B.C. (1993). A Demming Approach to Recruiting: The National Institute of Neurological Diseases and Stroke (NINDS) t-PA Stroke Trial Experience. In: del Zoppo, G.J., Mori, E., Hacke, W. (eds) Thrombolytic Therapy in Acute Ischemic Stroke II. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78061-5_41
Download citation
DOI: https://doi.org/10.1007/978-3-642-78061-5_41
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-56442-3
Online ISBN: 978-3-642-78061-5
eBook Packages: Springer Book Archive